Gene: RFX5
Official Full Name: regulatory factor X5provided by HGNC
Gene Summary: A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO06817 | RFX5 Knockout cell line (HeLa) | Human | RFX5 | 1:3~1:6 | Negative | Online Inquiry |
KO06818 | RFX5 Knockout cell line (HCT 116) | Human | RFX5 | 1:2~1:4 | Negative | Online Inquiry |
KO06819 | RFX5 Knockout cell line (HEK293) | Human | RFX5 | 1:3~1:6 | Negative | Online Inquiry |
KO06820 | RFX5 Knockout cell line (A549) | Human | RFX5 | 1:3~1:4 | Negative | Online Inquiry |
RFX5 Gene Knockout Cell Lines are specialized cellular models designed to facilitate the study of the RFX5 gene, which encodes a transcription factor involved in the regulation of immune responses and major histocompatibility complex (MHC) class II molecules. These knockout cell lines are engineered through various techniques, such as CRISPR/Cas9 genome editing, to produce a loss-of-function mutation, offering researchers a powerful tool to explore the gene's role in various biological processes and disease states.
The primary function of RFX5 is to act as a transcriptional activator, binding to specific DNA sequences and regulating the expression of genes necessary for immune system function. By utilizing RFX5 knockout cell lines, scientists can investigate the downstream effects of gene inactivation on cellular processes, signaling pathways, and interactions within the immune microenvironment. This makes them an invaluable resource in research focused on autoimmune diseases, cancer immunotherapy, and vaccine development.
In clinical and research settings, understanding the RFX5 gene's contribution to disease mechanisms can lead to the identification of novel therapeutic targets and biomarkers. Compared to alternative models, such as transient transfection systems or non-specific knockdown techniques, RFX5 knockout cell lines offer more stable and reproducible results that allow for in-depth functional studies and high-throughput screening applications. Their established genetic background enhances experimental consistency, providing a reliable platform for elucidating gene-function relationships.
For researchers and clinicians, RFX5 Gene Knockout Cell Lines are indispensable due to their capacity to advance our understanding of fundamental immunological processes and potential clinical implications. Leveraging our extensive expertise in cellular engineering and commitment to quality, our company provides researchers with superior products that drive scientific breakthroughs and innovation in the life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.